Xiangyu Medical Co. Ltd. A (688626) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Xiangyu Medical Co. Ltd. A stock ¥16.09, price ¥40.39, that is 60.2% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range ¥21.51 – ¥115.72 · fair‑value band ¥14.62 – ¥19.12 · the ¥40.39 price screens above the ¥16.09 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Xiangyu Medical Co. Ltd. A in your weekly email
Every Wednesday you see whether Xiangyu Medical Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Xiangyu Medical Co.,Ltd engages in the research, development, manufacture, and marketing of rehabilitation, physiotherapy, and pain management equipment in China.
Show moreShow less
It provides various therapy devices, such as smart occupational therapy, electrotherapy, sports therapy, rehabilitation, cold and heat therapy, gait, hydrotherapy, air compression therapy, phototherapy, traction tables, magnetic therapy, continuous passive motion (CPM), shock wave and ultrasound therapy, massage therapy, treatment tables and tilt tables, and microwave and shortwave therapy devices.
The company was incorporated in 2002 and is headquartered in Anyang, China.
Stock analysis
Xiangyu Medical Co. Ltd. A (688626) currently trades at ¥40.39, while our model-based Fair Value estimate is ¥16.09, 60% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥10.55 per share, and 1 of the 16 models we run sit above the ¥40.39 price.
Bear case: the Asset-Based group reads lowest at ¥1.62, and 15 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥14.62 (bear) to ¥19.12 (bull), the price of ¥40.39 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Xiangyu Medical Co. Ltd. A reported revenue of 768M CNY in FY2025 versus 523M CNY in FY2021, a compound +10.0%/yr. Reported net income was 78.7M CNY in FY2025, compounding −21.0%/yr from FY2021.
Key figures
Market cap 6.2B CNY (≈ $935M) Small · P/E ratio 79.2 · P/S ratio 7.97 · EPS (TTM) ¥0.5100 · Dividend yield 0.4% · Net margin 10.5% · Return on equity 4.0% · Return on assets (EBIT) 6.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −60%, 688626 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥1.62 to ¥51.12). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear¥14.62Fair Value ¥16.09Bull¥19.12
Price ¥40.39 · Downside -60.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.2812 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income¥9.11¥8.94¥9.1376
EPV¥8.15¥8.68¥9.1270
ROIC Compounder¥8.15¥8.68¥9.1270
All 16 models by family
Earnings-Based
Graham-Dodd¥3.34¥12.47¥16.8564
Lynch FV¥3.00¥4.28¥5.5761
PEG = 1.0¥3.00¥4.28¥5.5757
EPV¥8.15¥8.68¥9.1270
Dividend Discount
Gordon GGM¥2.26¥4.21¥5.9867
DDM Multi-Stage¥2.26¥3.78¥4.4867
Multiples
P/E Multiple¥8.12¥10.82¥13.5363
P/S Multiple¥6.27¥8.36¥10.4558
P/B Multiple¥38.34¥51.12¥63.9055
EV/EBIT¥8.50¥10.55¥12.6063
EV/EBITDA¥11.07¥13.98¥16.8864
EV/Revenue¥6.75¥8.62¥10.5052
Asset-Based
NCAV (Graham)¥1.07¥1.62¥2.0352
Economic Profit
Residual Income¥9.11¥8.94¥9.1376
ROIC Compounder¥8.15¥8.68¥9.1270
Growth Earnings
Growth-Adj P/E¥5.72¥8.17¥10.6267
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−17.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.7%
Dividend (yield on the price)0.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.45% → 10%
Compare Xiangyu Medical Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 321 stocks
Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−60.2% · Below median
Profitability
Return on equity (12 months)4.0% · Below median
Return on assets2.4% · Above median
Net margin (12 months)10.5% · Above median
Operating margin (12 months)0.8% · Below median
Growth and dividend
Revenue growth (quarter YoY)4.1% · Below median
Dividend yield (12 months)0.4% · Bottom 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)79.2× · Priciest 25%
P/B3.05× · Pricier than median
P/S (12 months)7.97× · Priciest 25%
EV/EBITDA61.7× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)21· sector 36
PAST (return on equity)16· sector 16
HEALTH (low debt)0· sector 98
DIVIDEND (yield)9· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Xiangyu Medical Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688626
Frequently asked questions
Is Xiangyu Medical Co. Ltd. A (688626) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ¥16.09 versus a price of ¥40.39, about 60% lower (overvalued).
What is the fair value of 688626?
Our model-based fair value for Xiangyu Medical Co. Ltd. A is ¥16.09 (as of Nov 6, 2026), built from audited fundamentals. The current price: ¥40.39.
What is the quality score of 688626?
Xiangyu Medical Co. Ltd. A has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Xiangyu Medical Co. Ltd. A (688626)?
Our model-based price target is the fair value of ¥16.09 (as of Nov 6, 2026) from 16 valuation models. Cautious scenario ¥14.62, optimistic scenario ¥19.12. It is a calculation from audited fundamentals, not an analyst target.
What is the Xiangyu Medical Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥16.09, about 60% lower versus a price of ¥40.39 (overvalued). Cautious scenario ¥14.62, optimistic scenario ¥19.12. The calculation is refreshed regularly with new filings.
What is the revenue of Xiangyu Medical Co. Ltd. A (688626)?
Xiangyu Medical Co. Ltd. A reported trailing-twelve-month revenue of about 782M CNY (latest available figure, as of Nov 6, 2026).
Does Xiangyu Medical Co. Ltd. A pay a dividend?
Xiangyu Medical Co. Ltd. A currently shows a dividend yield of 0.45% relative to its recent price (as of Nov 6, 2026).
What is the intrinsic value of Xiangyu Medical Co. Ltd. A (688626)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xiangyu Medical Co. Ltd. A it is ¥16.09 per share (as of Nov 6, 2026), against a price of ¥40.39. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Xiangyu Medical Co. Ltd. A stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 688626 trades above its calculated fair value: price ¥40.39, fair value ¥16.09, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688626?
No. The price is what the market pays today (¥40.39); the fair value is what the company's own numbers justify (¥16.09). For Xiangyu Medical Co. Ltd. A the two are ¥24.30 per share apart. That gap is exactly why we show both numbers side by side.
How much is Xiangyu Medical Co. Ltd. A worth?
The market values Xiangyu Medical Co. Ltd. A at about 6.2B CNY (market capitalisation, as of Nov 6, 2026). Per share that is ¥40.39; our models calculate a fair value of ¥16.09 per share.
What do the bullish and bearish scenarios say about 688626?
Our models span a range for Xiangyu Medical Co. Ltd. A: cautious scenario ¥14.62, base ¥16.09, optimistic ¥19.12 per share (as of Nov 6, 2026, price ¥40.39). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688626?
Xiangyu Medical Co. Ltd. A trades at a price-to-earnings ratio of 79.2 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥16.09 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2021 to 2025), reported earnings, FY2025 ex one-offs: 42.2. Other multiples: P/B 3.1, P/S 8.0, EV/EBITDA 61.7.
How solid is the balance sheet of Xiangyu Medical Co. Ltd. A (688626)?
Balance-sheet figures for Xiangyu Medical Co. Ltd. A (as of Nov 6, 2026): return on equity 4.0%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 688626 from its 52-week high?
Xiangyu Medical Co. Ltd. A trades at ¥40.39, about 53% below its 52-week high of ¥86.80 and 11% above the low of ¥36.25 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥16.09 is for.
Which stocks are comparable to Xiangyu Medical Co. Ltd. A?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Xiangyu Medical Co. Ltd. A stock attractive at the current price?
The data as of Nov 6, 2026: price ¥40.39, calculated fair value ¥16.09 (−60%), Quality Score 55/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688626 calculated?
We run Xiangyu Medical Co. Ltd. A through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥16.09, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Xiangyu Medical Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Xiangyu Medical Co. Ltd. A (688626)?
The closing price on Nov 6, 2026 was ¥40.39. Our model-based fair value is ¥16.09, about 60% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Xiangyu Medical Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥19.12). The favourable scenario is already priced in. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Xiangyu Medical Co. Ltd. A
How large is the market capitalisation of Xiangyu Medical Co. Ltd. A (688626)?
The market capitalisation of Xiangyu Medical Co. Ltd. A is 6.2B CNY (≈ $935M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Xiangyu Medical Co. Ltd. A (688626)?
The price-to-sales ratio of Xiangyu Medical Co. Ltd. A is 7.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Xiangyu Medical Co. Ltd. A (688626)?
Earnings per share at Xiangyu Medical Co. Ltd. A are ¥0.5100 (price ÷ EPS = P/E 79.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Xiangyu Medical Co. Ltd. A (688626)?
The dividend yield of Xiangyu Medical Co. Ltd. A is 0.4% (payout 35.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Xiangyu Medical Co. Ltd. A (688626)?
The net margin of Xiangyu Medical Co. Ltd. A is 10.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Xiangyu Medical Co. Ltd. A (688626)?
The return on equity (ROE) of Xiangyu Medical Co. Ltd. A is 4.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xiangyu Medical Co. Ltd. A (688626)?
On an EBIT basis the return on assets of Xiangyu Medical Co. Ltd. A is 6.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Xiangyu Medical Co. Ltd. A (688626)?
The operating margin of Xiangyu Medical Co. Ltd. A is 0.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Xiangyu Medical Co. Ltd. A (688626)?
Revenue at Xiangyu Medical Co. Ltd. A is growing +4.1% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Xiangyu Medical Co. Ltd. A (688626)?
Earnings per share at Xiangyu Medical Co. Ltd. A are growing +21.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Xiangyu Medical Co. Ltd. A (688626) generate?
The free cash flow of Xiangyu Medical Co. Ltd. A is −97.4M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Xiangyu Medical Co. Ltd. A (688626) hold?
Xiangyu Medical Co. Ltd. A holds more cash than debt, 378M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Xiangyu Medical Co. Ltd. A in the live analysis
One click puts Xiangyu Medical Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026